Oncolys BioPharma Inc (4588)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oncolys BioPharma Inc (4588) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013986
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncolys BioPharma Inc (Oncolys) is a biotechnology company that discovers, and develops treatments for cancer and infectious diseases. The company imports and exports oncolytic viruses, drugs and medicines, and tumor diagnostic agents. Its pharmaceutical pipeline products include OBP-301, OBP-801, OBP-601, OBP-AI-001 and OBP-AI-002. Oncolys offers diagnostic pipeline such as OBP-401 and OBP-1101. Oncolys research and develops oncolytic virus drugs for infectious diseases, molecular targeted anti-cancer drugs and tumor diagnostic agents. The company also provides consulting services for development of biotechnology drugs. It operates through its offices located in Tokyo, Kobe and Okayama. Oncolys is headquartered in Tokyo, Japan.

Oncolys BioPharma Inc (4588) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oncolys BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Liquid Biotech Raises USD2 Million in Seed Financing 11
Partnerships 12
Oncolys BioPharma Enters into Option Agreement with LBR Regulatory and Clinical Consulting Services 12
Oncolys BioPharma Enters into Research Agreement with Juntendo University 13
Oncolys Biopharma Enters into Research Agreement with Osaka University 14
Oncolys BioPharma Enters into Research Agreement with Kyoto Prefectural University of Medicine 15
Oncolys BioPharma Enters into Agreement with National Cancer Center Hospital 16
Oncolys BioPharma Enters into Research Agreement with Kyoto University 17
Licensing Agreements 18
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Oncolys BioPharma 18
Medigen and Oncolys BioPharma Enter into Licensing Agreement with Jiangsu Hengrui 19
Wonik Cube Amends Licensing Agreement with Oncolys BioPharma 20
Equity Offering 21
Oncolys BioPharma Raises Funds through Private Placement of Shares 21
Oncolys BioPharma Inc – Key Competitors 22
Oncolys BioPharma Inc – Key Employees 23
Oncolys BioPharma Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Clinical Trials 25
Aug 31, 2016: Protocol Submission of OBP-301 (Telomelysin) for Phase II Clinical Trial in the United States 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncolys BioPharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oncolys BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
Oncolys BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Liquid Biotech Raises USD2 Million in Seed Financing 11
Oncolys BioPharma Enters into Option Agreement with LBR Regulatory and Clinical Consulting Services 12
Oncolys BioPharma Enters into Research Agreement with Juntendo University 13
Oncolys Biopharma Enters into Research Agreement with Osaka University 14
Oncolys BioPharma Enters into Research Agreement with Kyoto Prefectural University of Medicine 15
Oncolys BioPharma Enters into Agreement with National Cancer Center Hospital 16
Oncolys BioPharma Enters into Research Agreement with Kyoto University 17
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Oncolys BioPharma 18
Medigen and Oncolys BioPharma Enter into Licensing Agreement with Jiangsu Hengrui 19
Wonik Cube Amends Licensing Agreement with Oncolys BioPharma 20
Oncolys BioPharma Raises Funds through Private Placement of Shares 21
Oncolys BioPharma Inc, Key Competitors 22
Oncolys BioPharma Inc, Key Employees 23
Oncolys BioPharma Inc, Other Locations 24
Oncolys BioPharma Inc, Subsidiaries 24

★海外企業調査レポート[Oncolys BioPharma Inc (4588)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vergnet SA (ALVER)-エネルギー分野:企業M&A・提携分析
    Summary Vergnet SA (Vergnet) is a renewable energy company. It designs, develops, and manufactures renewable solutions. The company offers wind, solar and hybrid energy solutions besides solar applications. Through its technology Hybrid Wizard, Vergnet offers real-time hybrid controller solutions fo …
  • Sekisui House, Ltd.:企業の戦略・SWOT・財務情報
    Sekisui House, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sekisui House, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sanwa Holdings Corporation:企業の戦略・SWOT・財務情報
    Sanwa Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Sanwa Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Saline Water Conversion Corp:企業の戦略的SWOT分析
    Saline Water Conversion Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • New York & Company, Inc.:企業の戦略・SWOT・財務情報
    New York & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary New York & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Medical Properties Trust, Inc.:企業のM&A・事業提携・投資動向
    Medical Properties Trust, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medical Properties Trust, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Hetero Drugs Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Hetero Drugs Ltd (Hetero) is a manufacturer of active pharmaceutical ingredients, intermediate chemicals and finished dosages. The company specializes in process chemistry, API manufacturing, formulation development, manufacturing and commercialization of bio-generics, and also offers custom …
  • Usg Corporation:企業の戦略・SWOT・財務分析
    Usg Corporation - Strategy, SWOT and Corporate Finance Report Summary Usg Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Clearside BioMedical Inc (CLSD):企業の財務・戦略的SWOT分析
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • Talon Petroleum Ltd (TPD):石油・ガス:M&Aディール及び事業提携情報
    Summary Talon Petroleum Ltd (Talon Petroleum) is an oil and gas company. The company operates in the business of exploration, development, and production of petroleum resources. Its principal project include Mosman Rockingham (MR) Olmos project, which is located in McMullen County, Texas. Talon Petr …
  • City National Wealth Management:企業の戦略・SWOT・財務情報
    City National Wealth Management - Strategy, SWOT and Corporate Finance Report Summary City National Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • FlightSafety International Inc:企業の戦略・SWOT・財務分析
    FlightSafety International Inc - Strategy, SWOT and Corporate Finance Report Summary FlightSafety International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Corning Incorporated (GLW)-エネルギー分野:企業M&A・提携分析
    Summary Corning Incorporated (Corning) manufactures and sells ceramics, specialty glasses and related materials. The company’s product portfolio includes glass substrates, which find application in LCD televisions, computer monitors and laptops; optical fibers, cable, hardware and equipment for tele …
  • Mediware Information Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediware Information Systems Inc (Mediware), a subsidiary of TPG Capital is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solution …
  • A1M Pharma AB (A1M)-製薬・医療分野:企業M&A・提携分析
    Summary A1M Pharma AB (A1M Pharma) develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. The company offers ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and elimina …
  • Ricoh Imaging Co Ltd:企業の戦略的SWOT分析
    Ricoh Imaging Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mtr Corporation Ltd:企業の戦略・SWOT・財務分析
    Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dai Nippon Printing Co., Ltd.:企業の戦略・SWOT・財務分析
    Dai Nippon Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dai Nippon Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Intercontinental Hotels Group Plc
    Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Fortune Electric Co Ltd (1519):企業の財務・戦略的SWOT分析
    Summary Fortune Electric Co Ltd (Fortune Electric) is a power company that manufactures and markets transformers and accessories. The company provides products such as distribution transformers, power transformers, cast resin transformers and amorphous metal alloy core transformers, among others. It …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆